查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1806394

HIV/AIDS 诊断市场（按检测类型、产品类型、检测方法、最终用户和应用）—2025-2030 年全球预测

HIV or AIDS Diagnostics Market by Test Type, Type of Product, Testing Method, End-User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2024 年爱滋病毒/爱滋病诊断市场价值将达到 24.5 亿美元，2025 年将成长至 26 亿美元，复合年增长率为 6.34%，到 2030 年将达到 35.4 亿美元。

主要市场统计数据
基准年2024年 24.5亿美元
预计2025年 26亿美元
预测年份 2030 35.4亿美元
复合年增长率（%） 6.34%

HIV/AIDS 诊断解决方案的快速发展改善了早期发现和患者治疗效果，并重新定义了策略伙伴关係

近年来，在分子生物学、数位健康以及对病毒病理生理学的深入了解推动下，爱滋病毒/爱滋病诊断领域发生了重大变化。如今的诊断生态系统已远远超越传统实验室，融合了快速即时诊断平台、居家自测解决方案以及为临床医生提供即时洞察的整合数据分析。早期精准检测仍然是有效患者管理的基础，多重抗体检测和下一代病毒载量技术等进展正在缩小灵敏度和周转时间的关键差距。此外，诊断研发人员、公共卫生机构和社区组织之间的合作正在扩展检测服务，以确保服务匮乏的人群能够公平地获得检测服务。

新的即时诊断技术和综合护理模式正在改变全球爱滋病毒/爱滋病诊断格局

HIV/AIDS 诊断领域的创新正以前所未有的速度发展，这得益于新型即时诊断技术和整合护理模式，这些模式解决了长期以来在获取和速度方面面临的挑战。虽然实验室平台在病毒量量化方面依然拥有无与伦比的灵敏度，但可携式免疫检测测定仪和核酸扩增设备的普及使临床医生即使在偏远地区也能现场获取结果。同时，自测检测套组正在赋能个人，使其能够积极参与自身健康，减少污名化，并扩大传统基础设施有限的社区的检测覆盖率。

评估美国关税对 2025 年爱滋病毒/爱滋病诊断供应链、定价和全球市场动态的累积影响

2025年美国关税为爱滋病毒/爱滋病诊断供应链带来了新的动态，影响了成本结构、筹资策略和区域伙伴关係。对原产于受影响地区的试剂和耗材征收关税，促使一些供应商重新评估其采购，并考虑区域製造地。因此，製造商正在加快步伐，建立关键检测零件的本地生产设施，以减少对跨境运输的依赖，并降低未来关税波动的影响。

揭示爱滋病毒/爱滋病诊断中测试类型、产品、测试方法、最终用户和应用方面的关键市场细分洞察

当全面考虑定义 HIV/AIDS 诊断市场的各种测试类型、产品、调查方法、最终用户设定和应用领域时，就会对 HIV/AIDS 诊断有细緻的了解。抗体检测仍然是基础，包括酵素结合免疫吸附检测法、快速免疫层析和确认性西方墨点法，每种方法都针对不同的操作需求和灵敏度要求。利用流式细胞技术、基于 PCR 的扩增和创新的微流体方法，CD4 细胞计数和病毒量定量对于疾病分期和治疗监测仍然至关重要。同时，从专门的酵素基材到冷冻干燥 PCR 预混液等消耗品和试剂，以及将样本製备、扩增和检测整合到简化的工作流程中的仪器和套件，正在塑造诊断格局。

分析影响美洲、欧洲、中东和非洲以及亚太地区爱滋病毒/爱滋病诊断成长和创新的关键区域动态

美洲地区由成熟的北美医疗保健体系和新兴的拉丁美洲市场组成，该地区正大力推广先进的分子检测技术，同时公共卫生筛检倡议也不断扩展。该地区的利害关係人受益相关人员强有力的法律规范、大量的研发投入以及政府与私人实验室之间的合作，从而促进了早期检测宣传活动和治疗监测计画的开展。相较之下，欧洲、中东和非洲地区的需求则呈现出多样化的特征：高所得国家正在部署次世代定序仪进行抗药性分析，而低收入地区则利用照护现场和自我检测解决方案来克服基础设施限制，并惠及服务不足的社区。

介绍推动爱滋病毒/爱滋病诊断领域创新、伙伴关係和策略倡议的领先产业参与者

在策略性收购、突破性创新和广泛分销网络的推动下，领先的诊断公司持续塑造着爱滋病毒/爱滋病检测格局。全球医疗科技公司正透过与专注于快速检测开发和数位化互联解决方案的生物科技新兴企业建立有针对性的合作伙伴关係，强化其产品组合。这些伙伴关係关係催生了将血清学、细胞学和分子检测与云端基础彙报相结合的整合平台，满足了实验室准确性和照护现场便利性的双重需求。

为行业领导者提供可行的建议，以应对诊断领域的监管变化、技术进步和竞争压力

为了应对爱滋病毒/爱滋病诊断技术的复杂演变，产业领导者应优先考虑供应链多元化，建立区域製造联盟并制定紧急采购通讯协定。采用模组化仪器设计和灵活的试剂格式，可以快速回应关税波动和监管变化。同时，将人工智慧主导的分析技术融入诊断工作流程，可增强预测能力，支援临床决策，并优化疾病监测工作。在此技术基础上，鼓励利害关係人与远端医疗服务提供相关人员和社区组织建立伙伴关係，以扩大和改善检测结果呈阳性后的医疗服务可近性。

概述一种利用一手资料和二手资料对爱滋病毒/爱滋病诊断市场进行全面分析的稳健调查方法

这项研究采用了严谨的多层次方法，结合了对关键意见领袖、实验室主任、监管专家和重点地区采购负责人的初步访谈。二次研究则广泛研究了同行评审日誌、技术白皮书、专利申请、监管资料库和公共卫生出版物，以了解最新的创新和政策发展。数据经过三角测量，以检验趋势、识别新兴应用，并协调专有资讯和开放原始码资讯之间的差异。

摘要关键发现和策略意义，为不断发展的爱滋病毒/爱滋病诊断生态系统中的相关人员提供指导

总而言之，HIV/AIDS 诊断领域正处于一个关键的十字路口，其特点是技术创新加速、监管格局不断变化以及对分散检测的重视。先进的即时诊断平台、数位健康整合和模组化试剂的相互作用正在重新定义临床路径，并为患者提供及时、可操作的结果。基于基础设施成熟度、政策框架和公私合作伙伴关係的地区差异凸显了製定客製化策略的必要性，以同时满足大量的筛检需求和专业的监测要求。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 照护现场爱滋病毒自我检测套组与行动医疗应用程式结合，可改善患者与照护之间的互动
  • 在分散环境中采用基于 CRISPR 的诊断方法进行快速、超灵敏的 HIV 病毒量定量
  • 第四代多重抗原抗体检测对早期发现急性HIV感染的影响
  • 扩展的多重 PCR 面板可在单次测试中同时检测 HIV、C型肝炎和结核病合併感染
  • 基于人工智慧的影像分析在流式细胞技术中的新用途，用于在 HIV 监测中自动计数 CD4 T 细胞
  • 发展整合蛋白质体学、代谢体学和转录组学的多组体学物标记组，用于对爱滋病毒疾病进展进行分层

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章：2025年美国关税的累积影响

8. HIV/AIDS 诊断市场（依检测类型）

  • 抗体检测
    • ELISA/EIA
    • 快速检测
    • 蛋白质印迹试验
  • CD4侦测
  • 病毒量测试

9. HIV/AIDS 诊断市场（依产品类型）

  • 耗材和试剂
  • 设备和套件
  • 软体
  • 测试服务

第 10 章 HIV/AIDS 诊断市场（按测试方法）

  • 实验室检测
  • 就地检验
  • 自检

第 11 章。 HIV/AIDS 诊断市场（按最终用户）

  • 血库和输血中心
  • 诊断中心
  • 居家照护环境
  • 医院和诊所
  • 研究所

第 12 章：爱滋病毒/爱滋病诊断市场（按应用）

  • 疾病进展
  • 监控
  • 筛检

13.美国HIV/AIDS诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 欧洲、中东和非洲爱滋病毒/爱滋病诊断市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

15. 亚太地区爱滋病毒/爱滋病诊断市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • F. Hoffmann-La Roche Ltd.
    • ACON Laboratories
    • Beckman Coulter, Inc.
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories
    • bioMerieux SA
    • Chembio Diagnostics, Inc.
    • Danaher Corporation
    • DiaSorin SpA
    • ELITechGroup
    • Euroimmun Medizinische Labordiagnostika AG
    • Hologic, Inc.
    • InBios International, Inc.
    • OraSure Technologies
    • Ortho Clinical Diagnostics, Inc.
    • SD Biosensor Inc.
    • Siemens Healthineers AG
    • Thermo Fisher Scientific, Inc.
    • Trinity Biotech plc
    • Viracor Eurofins Diagnostic Services
    • Wondfo Biotech Co. Ltd.

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

Product Code: MRR-437E9896A55D

The HIV or AIDS Diagnostics Market was valued at USD 2.45 billion in 2024 and is projected to grow to USD 2.60 billion in 2025, with a CAGR of 6.34%, reaching USD 3.54 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.45 billion
Estimated Year [2025] USD 2.60 billion
Forecast Year [2030] USD 3.54 billion
CAGR (%) 6.34%

How Rapid Advances and Strategic Collaboration Are Redefining HIV and AIDS Diagnostic Solutions to Enhance Early Detection and Patient Outcomes

The landscape of HIV and AIDS diagnostics has undergone remarkable transformation in recent years, driven by breakthroughs in molecular biology, digital health, and a deeper understanding of viral pathophysiology. Today's diagnostic ecosystem extends far beyond traditional laboratory settings, incorporating rapid point-of-care platforms, home self-testing solutions, and integrated data analytics that empower clinicians with real-time insights. Early and accurate detection remains the cornerstone of effective patient management, and advances such as multiplex antibody assays and next-generation viral load techniques are closing critical gaps in sensitivity and turnaround time. Furthermore, collaborations between diagnostic developers, public health institutions, and community organizations have amplified reach, ensuring that underserved populations gain equitable access to testing services.

As regulatory agencies accelerate approval pathways for novel diagnostics, there has been an influx of innovative platforms designed to streamline workflows and reduce overall testing costs. Digital connectivity features now embed seamlessly into laboratory information management systems, enabling secure, interoperable data exchange and predictive analytics for patient outcomes. In parallel, the rise of decentralized testing models, supported by portable instruments and smartphone-enabled readers, is bringing HIV diagnostics closer to the point of need. Looking forward, precision diagnostics and adaptive surveillance strategies promise to redefine how clinicians and public health leaders anticipate, monitor, and respond to the evolving HIV and AIDS epidemic.

Emerging Point-Of-Care Technologies and Integrated Care Models Are Driving Transformative Shifts in the Global HIV and AIDS Diagnostic Landscape

Innovation in HIV and AIDS diagnostics is unfolding at an unprecedented pace, catalyzed by emerging point-of-care technologies and integrated care models that address long-standing challenges in access and speed. Laboratory-based platforms continue to offer unparalleled sensitivity for viral load quantification, yet the proliferation of portable immunoassay readers and nucleic acid amplification devices is enabling clinicians to deliver same-visit results in remote settings. Meanwhile, self-testing kits are empowering individuals to engage proactively with their health, reducing stigma and expanding testing coverage in communities where traditional infrastructure may be limited.

In addition, partnerships between diagnostic manufacturers and digital health firms are producing solutions that integrate test results with electronic health records, telemedicine services, and patient support applications. These alliances are accelerating data-driven decision making, driving adherence monitoring, and facilitating linkage to care. Concurrently, regulatory frameworks are evolving to accommodate emergency use authorizations and expedited reviews, especially for diagnostics that demonstrate high clinical utility. Collectively, these trends are reshaping the diagnostic ecosystem, fostering an environment where agility, collaboration, and patient-centric design converge to elevate the standard of HIV and AIDS testing globally.

Assessing the Cumulative Impact of United States Tariffs on HIV and AIDS Diagnostic Supply Chains, Pricing Structures, and Global Market Dynamics by 2025

United States tariffs implemented in 2025 have introduced new dynamics across the HIV and AIDS diagnostic supply chain, affecting cost structures, procurement strategies, and regional partnerships. Reagents and consumables that originate from targeted regions have become subject to incremental duties, leading some suppliers to reevaluate sourcing and to consider regional manufacturing hubs. As a result, manufacturers have accelerated efforts to establish localized production facilities for critical assay components, reducing reliance on cross-border shipments and mitigating exposure to future tariff fluctuations.

These shifts have also prompted diagnostic firms to optimize their product portfolios, prioritizing assays with higher value-added features that can absorb additional costs without compromising clinical affordability. In parallel, research and development investments are focusing on alternative chemistries and modular instrument designs that facilitate in-country assembly and calibration. Even as procurement departments grapple with revised pricing models, procurement teams and policy makers are collaborating to secure volume-based agreements and to streamline customs processes.

Looking ahead, the tariff environment underscores the importance of supply chain resilience. Diagnostic companies are forging strategic alliances with regional suppliers, reinforcing distribution networks, and harnessing digital supply-chain monitoring to anticipate disruptions. Through these adaptive strategies, stakeholders are navigating the tariff landscape while preserving access to essential HIV and AIDS diagnostic services.

Unveiling Critical Market Segmentation Insights Spanning Test Types, Products, Testing Methods, End Users, and Applications in HIV and AIDS Diagnostics

A nuanced understanding of HIV and AIDS diagnostics emerges when considering the variety of test types, products, methodologies, end-user settings, and application areas that collectively define the market. Antibody tests remain fundamental, encompassing enzyme-linked immunosorbent assays, rapid immunochromatographic platforms, and confirmatory Western blot techniques, each catering to distinct operational needs and sensitivity requirements. CD4 cell enumeration and viral load quantification continue to be indispensable for disease staging and treatment monitoring, leveraging flow cytometry, PCR-based amplifiers, and innovative microfluidic approaches. In parallel, the diagnostic landscape is shaped by consumables and reagents, from specialized enzyme substrates to lyophilized PCR master mixes, alongside instruments and kits that integrate sample preparation, amplification, and detection into streamlined workflows.

Software solutions for data management, connectivity, and analytics are emerging as key differentiators, enabling laboratories to aggregate patient data, track epidemiological trends, and support telehealth initiatives. Testing services delivered through centralized laboratories coexist with onsite testing models, such as point-of-care platforms offering rapid turnaround in community clinics, and self-testing kits that empower individuals to conduct HIV screening at home. Blood banks and transfusion centers, diagnostic centers, home care settings, hospitals, clinics, and research institutes each demand tailored diagnostic capabilities, ranging from high-throughput screening to specialized immunophenotyping. Finally, the applications of HIV and AIDS diagnostics span initial screening for seroconversion, monitoring therapeutic efficacy through viral suppression metrics, and assessing disease progression via CD4 count trajectories, driving the continued diversification of assay portfolios.

Analyzing Key Regional Dynamics Shaping Growth and Innovation in HIV and AIDS Diagnostics across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics profoundly influence how HIV and AIDS diagnostics evolve, with the Americas, comprising both mature North American healthcare systems and emerging Latin American markets, demonstrating robust adoption of advanced molecular assays alongside expanded public health screening initiatives. Stakeholders in this region benefit from strong regulatory frameworks, significant R&D investments, and collaborations between government agencies and private sector laboratories, facilitating early detection campaigns and treatment monitoring programs. By contrast, Europe, the Middle East, and Africa present a diverse tapestry of needs, where high-income countries deploy next-generation sequencing for drug resistance analysis and lower-income regions leverage point-of-care and self-testing solutions to overcome infrastructure constraints and reach underserved communities.

Meanwhile, the Asia-Pacific region is witnessing rapid uptake of cost-effective immunoassays, coupled with an increasing emphasis on digital integration and telemedicine platforms. Governments across this region are investing in universal screening programs and public-private partnerships to enhance laboratory capacity and distribute testing kits to rural areas. Multinational diagnostic firms are tailoring portfolios to local regulatory requirements and price sensitivity, while domestic manufacturers are scaling production to meet regional demand. Together, these regional trends underscore the importance of context-specific strategies, where regulatory alignment, supply chain agility, and culturally sensitive outreach determine the success of diagnostic initiatives.

Profiling Leading Industry Players Driving Innovation, Partnerships, and Strategic Initiatives in the HIV and AIDS Diagnostics Sector

A cadre of leading diagnostic companies continues to shape the HIV and AIDS testing landscape, propelled by strategic acquisitions, breakthrough innovations, and expansive distribution networks. Global healthcare technology firms have fortified their portfolios through targeted collaborations with biotechnology startups specializing in rapid test development and digital connectivity solutions. These partnerships are yielding integrated platforms that combine serological, cellular, and molecular assays with cloud-based reporting, meeting the dual demands of laboratory precision and point-of-care convenience.

In response to tariff-induced supply challenges, certain firms have relocated assembly lines closer to key markets, optimizing logistical efficiency and accelerating product delivery. At the same time, a subset of diagnostics innovators is pioneering next-generation technologies-such as CRISPR-based detection systems and microarray workflows-to enable ultra-sensitive, multiplexed screening in resource-limited settings. Meanwhile, several companies are expanding their market reach through alliances with nonprofit organizations and global health initiatives, ensuring their assays are incorporated into large-scale screening and treatment programs. Collectively, these strategic moves and technological investments underscore the competitive rigor and collaborative spirit driving the industry forward.

Delivering Actionable Recommendations for Industry Leaders to Navigate Regulatory Changes, Technological Advancements, and Competitive Pressures in Diagnostics

To navigate the evolving complexities of HIV and AIDS diagnostics, industry leaders should prioritize the diversification of supply chains by forging regional manufacturing alliances and establishing contingency sourcing protocols. Embracing modular instrument designs and flexible reagent formats will enable rapid adaptation to tariff fluctuations and regulatory changes. Simultaneously, integrating artificial intelligence-driven analytics into diagnostic workflows can enhance predictive capabilities, support clinical decision making, and optimize disease surveillance efforts. Building on these technological foundations, stakeholders are encouraged to cultivate partnerships with telehealth providers and community-based organizations to extend reach and improve linkage to care following positive test results.

Investing in workforce development and training programs will ensure that healthcare professionals and laboratory technicians remain proficient in emerging diagnostic methodologies and digital platforms. Moreover, engaging proactively with policymakers can shape favorable regulatory environments for novel diagnostics, including emergency use pathways and accelerated approval mechanisms. Finally, differentiating service offerings through value-added features-such as interoperability, data security, and patient engagement modules-will distinguish organizations in a competitive marketplace and drive sustainable growth.

Outlining a Robust Research Methodology Leveraging Primary and Secondary Sources for Comprehensive Analysis of the HIV and AIDS Diagnostics Market

This research undertook a rigorous, multi-tiered methodology combining primary interviews with key opinion leaders, laboratory directors, regulatory experts, and procurement officers across major geographic regions. Secondary research encompassed a thorough review of peer-reviewed journals, technical whitepapers, patent filings, regulatory databases, and public health agency publications to capture the latest innovations and policy developments. Data were triangulated to validate trends, identify emerging applications, and reconcile discrepancies between proprietary and open-source information.

Quantitative analyses were conducted using anonymized datasets from leading diagnostic manufacturers and service providers, while qualitative insights were gathered through structured discussions with healthcare practitioners and patient advocacy groups. The research framework also integrated comparative case studies of high-impact implementation projects, highlighting best practices in deployment, training, and quality assurance. Finally, findings were subjected to expert peer review to ensure accuracy, relevance, and strategic applicability for stakeholders across the HIV and AIDS diagnostics ecosystem.

Summarizing Core Findings and Strategic Implications to Guide Stakeholders in the Evolving HIV and AIDS Diagnostics Ecosystem

In conclusion, the HIV and AIDS diagnostics sector is at a pivotal juncture, characterized by accelerating technological innovation, shifting regulatory landscapes, and heightened emphasis on decentralizing testing. The interplay of advanced point-of-care platforms, digital health integrations, and modular reagents is redefining clinical pathways and empowering patients with timely, actionable results. Regional nuances-driven by infrastructure maturity, policy frameworks, and public-private collaborations-underscore the need for tailored strategies that address both high-volume screening demands and specialized monitoring requirements.

As tariff regimes introduce new considerations for supply chain resilience and cost management, diagnostic organizations must remain agile, investing in local production capabilities and strategic partnerships. By aligning product development roadmaps with emerging digital tools and evolving care models, stakeholders can enhance diagnostic reach, improve patient outcomes, and sustain competitive differentiation. Ultimately, the synthesis of these trends presents an opportunity for the industry to chart a course toward more accessible, efficient, and patient-centric HIV and AIDS diagnostic solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Integration of point-of-care HIV self-testing kits with mobile health apps to improve patient linkage to care
  • 5.2. Adoption of CRISPR-based diagnostics for rapid ultra-sensitive HIV viral load quantification in decentralized settings
  • 5.3. Impact of fourth generation combination antigen antibody assays on early acute HIV infection detection
  • 5.4. Expansion of multiplex PCR panels enabling simultaneous detection of HIV hepatitis C and tuberculosis co-infection in a single assay
  • 5.5. Emerging use of AI powered image analysis in flow cytometry for automated CD4 T cell enumeration in HIV monitoring
  • 5.6. Development of multi omics biomarker panels integrating proteomics metabolomics and transcriptomics for HIV disease progression stratification

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. HIV or AIDS Diagnostics Market, by Test Type

  • 8.1. Introduction
  • 8.2. Antibody Tests
    • 8.2.1. ELISA/EIA
    • 8.2.2. Rapid Tests
    • 8.2.3. Western Blot Test
  • 8.3. CD4 Tests
  • 8.4. Viral Load Tests

9. HIV or AIDS Diagnostics Market, by Type of Product

  • 9.1. Introduction
  • 9.2. Consumables & Reagents
  • 9.3. Instruments & Kits
  • 9.4. Software
  • 9.5. Testing Services

10. HIV or AIDS Diagnostics Market, by Testing Method

  • 10.1. Introduction
  • 10.2. Laboratory-Based Testing
  • 10.3. Point-Of-Care Testing
  • 10.4. Self-Testing

11. HIV or AIDS Diagnostics Market, by End-User

  • 11.1. Introduction
  • 11.2. Blood Banks & Transfusion Centers
  • 11.3. Diagnostic Centers
  • 11.4. Home Care Settings
  • 11.5. Hospitals & Clinics
  • 11.6. Research Institutes

12. HIV or AIDS Diagnostics Market, by Application

  • 12.1. Introduction
  • 12.2. Disease Progression
  • 12.3. Monitoring
  • 12.4. Screening

13. Americas HIV or AIDS Diagnostics Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa HIV or AIDS Diagnostics Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific HIV or AIDS Diagnostics Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. F. Hoffmann-La Roche Ltd.
    • 16.3.3. ACON Laboratories
    • 16.3.4. Beckman Coulter, Inc.
    • 16.3.5. Becton, Dickinson and Company
    • 16.3.6. Bio-Rad Laboratories
    • 16.3.7. bioMerieux SA
    • 16.3.8. Chembio Diagnostics, Inc.
    • 16.3.9. Danaher Corporation
    • 16.3.10. DiaSorin S.p.A.
    • 16.3.11. ELITechGroup
    • 16.3.12. Euroimmun Medizinische Labordiagnostika AG
    • 16.3.13. Hologic, Inc.
    • 16.3.14. InBios International, Inc.
    • 16.3.15. OraSure Technologies
    • 16.3.16. Ortho Clinical Diagnostics, Inc.
    • 16.3.17. SD Biosensor Inc.
    • 16.3.18. Siemens Healthineers AG
    • 16.3.19. Thermo Fisher Scientific, Inc.
    • 16.3.20. Trinity Biotech plc
    • 16.3.21. Viracor Eurofins Diagnostic Services
    • 16.3.22. Wondfo Biotech Co. Ltd.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. HIV OR AIDS DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. HIV OR AIDS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. HIV OR AIDS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. HIV OR AIDS DIAGNOSTICS MARKET: RESEARCHAI
  • FIGURE 26. HIV OR AIDS DIAGNOSTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 27. HIV OR AIDS DIAGNOSTICS MARKET: RESEARCHCONTACTS
  • FIGURE 28. HIV OR AIDS DIAGNOSTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. HIV OR AIDS DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ELISA/EIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ELISA/EIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY RAPID TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY CD4 TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY CD4 TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY VIRAL LOAD TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY VIRAL LOAD TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS & KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY LABORATORY-BASED TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY LABORATORY-BASED TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SELF-TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SELF-TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY BLOOD BANKS & TRANSFUSION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY BLOOD BANKS & TRANSFUSION CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY DISEASE PROGRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY DISEASE PROGRESSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 64. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 65. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 66. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 67. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 68. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 69. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 71. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 73. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 75. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 77. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 78. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 79. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 80. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 81. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 82. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 83. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 84. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 85. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 86. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 87. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 88. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 91. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 93. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 94. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 95. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 96. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 97. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 98. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 99. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 100. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 101. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 102. CANADA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 103. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 105. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 106. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 107. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 108. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 109. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 110. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 111. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 112. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 113. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 114. MEXICO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 115. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 118. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 119. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 120. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 121. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 122. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 123. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 124. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 125. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 126. BRAZIL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 127. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 130. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 131. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 132. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 133. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 134. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 135. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 136. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 137. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 138. ARGENTINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED KINGDOM HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 165. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 168. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 169. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 170. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 171. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 172. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 173. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 174. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 175. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. GERMANY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 177. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 179. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 180. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 181. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 182. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 183. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 184. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 185. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 186. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 187. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. FRANCE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 189. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 192. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 193. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 194. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 195. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 196. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 197. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 198. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 199. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. RUSSIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 201. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 204. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 205. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 206. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 207. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 208. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 209. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 210. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 211. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. ITALY HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 213. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 215. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 216. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 217. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 218. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 219. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 220. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 221. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 222. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 223. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. SPAIN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 240. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 242. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 244. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 246. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 247. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. SAUDI ARABIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 252. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 253. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 254. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 255. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 256. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 257. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 258. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 259. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. SOUTH AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 261. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 263. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 264. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 265. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 266. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 267. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 268. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 269. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 270. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 271. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. DENMARK HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 276. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 278. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 280. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 281. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 282. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 283. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. NETHERLANDS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 285. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 288. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 289. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 290. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 291. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 292. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 293. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 294. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 295. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. QATAR HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 297. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 299. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 300. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 301. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 302. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 303. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 304. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 305. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 306. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 307. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 308. FINLAND HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 309. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 311. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 312. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 313. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 314. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 315. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 316. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD MILLION)
  • TABLE 317. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 318. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 319. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. SWEDEN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 321. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 323. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2024 (USD MILLION)
  • TABLE 324. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2025-2030 (USD MILLION)
  • TABLE 325. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 326. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 327. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2024 (USD MILLION)
  • TABLE 328. NIGERIA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025-2030 (USD M